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A B S T R A C T   
Background: UK primary-care referral guidance describes the signs, symptoms, and test results (“features”) of 
undiagnosed cancer. Guidance revision in 2015 liberalised investigation by introducing more low-risk features. 
We studied adults with cancer whose features were in the 2005 guidance (“Old-NICE”) or were introduced in the 
revision (“New-NICE”). We compared time to diagnosis between the groups, and its trend over 2006—2017. 
Methods: Clinical Practice Research Datalink records were analysed for adults with incident myeloma, breast, 
bladder, colorectal, lung, oesophageal, ovarian, pancreatic, prostate, stomach or uterine cancers in 1/1/ 
2006–31/12/2017. Cancer-specific features in the year before diagnosis were used to create New-NICE and Old- 
NICE groups. Diagnostic interval was time between the index feature and diagnosis. Semiparametric varying- 
coefficient analyses compared diagnostic intervals between New-NICE and Old-NICE groups over 1/1/ 
2006–31/12/2017. 
Results: Over all cancers (N  83,935), median (interquartile range) Old-NICE diagnostic interval rose over 
2006–2017, from 51 (20–132) to 64 (30–148) days, with increases in breast (15 vs 25 days), lung (103 vs 135 
days), ovarian (65⋅5 vs 100 days), prostate (80 vs 93 days) and stomach (72⋅5 vs 102 days) cancers. Median New- 
NICE values were consistently longer (99, 40–212 in 2006 vs 103, 42–236 days in 2017) than Old-NICE values 
over all cancers. After guidance revision, New-NICE diagnostic intervals became shorter than Old-NICE values for 
colorectal cancer. 
Conclusions: Despite improvements for colorectal cancer, scope remains to reduce diagnostic intervals for most 
cancers. Liberalised investigation requires protecting and enhancing cancer-diagnostic services to avoid their 
becoming a rate-limiting step in the diagnostic pathway.   
1. Introduction 
Early cancer detection is central to improving outcomes [1]. Most 
early-detection strategies focus on the timely recognition and 
investigation of people likely to have undiagnosed cancer [2–4]. As 
screening detects <6 % of cancer [5], UK strategies focus on promptly 
recognising the symptoms, signs or test results associated with undiag-
nosed cancer (“features of possible cancer”, or simply “features”) [6]. In 
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2005, UK suspected-cancer guidance was published, listing features 
warranting cancer testing or investigation [7]. 
The guidance was revised in 2011 for ovarian cancer [8], and in 2015 
for remaining cancers [2]. The aim was to expedite cancer diagnosis by 
lowering the risk of undiagnosed cancer warranting clinical action from 
5 % to 3 % [2], which was achieved by introducing more vague fea-
tures into the guidance [2,9]. The revised guidance is officially appli-
cable in England, and endorsed in Wales and Northern Ireland [10]. 
Our objective was to explore the timeliness of cancer diagnosis in 
England, Wales and Northern Ireland in 2006–2017 for 11 common 
internal cancers. We compared time from first feature to diagnosis be-
tween two groups: “Old-NICE” (with features of possible cancer in the 
original 2005 guidance) and “New-NICE” (only participants with fea-
tures introduced during guidance revision). We hypothesised that times 
to diagnosis would be longer for New-NICE than for Old-NICE partici-
pants, because diagnosing cancer is more challenging and may take 
longer when symptoms are vague [9,11–14]. We also hypothesised that 
the difference in time to diagnosis between New-NICE and Old-NICE 
groups would reduce over time, as evidence on vague cancer features 
emerged and was translated into practice by guidance revision [2,15]. 
2. Methods 
2.1. Study setting and design 
This serial, cross-sectional, primary-care study used UK Clinical 
Practice Research Datalink (CPRD GOLD) with linked National Cancer 
Registration and Analysis Service (NCRAS, Set 15) data. CPRD GOLD 
comprises prospective, coded, and anonymised medical records from 
>600 UK general practices, with 389 having NCRAS linkage [16]. The 
study examined participants in the year before their cancer diagnosis 
between 2006 and 2017. 
2.2. Inclusion and exclusion criteria 
Inclusion criteria:  
 Age 18 years  
 An incident diagnostic code recorded between 1st January 2006 and 
31st December 2017 for myeloma(ICD10 C90), breast(C50), 
bladder(C67), colorectal(C18–C20), lung(C34), oesophageal 
(C15), ovarian(C56), pancreatic(C25), prostate(C61), stomach 
(C16), or uterine(C54) cancer.  
 Practice registration 1 year before cancer diagnosis. 
These sites were selected because the revised guidance introduced 
new features of possible cancer for them, allowing participant grouping 
Table 1 
Cancer features sought in participants’ medical records in the year before 
diagnosis.  
Cancer site Features listed in NICE 2005 (“Old 
NICE”) 
Features added in NICE 
2015 (“New NICE”) 
Bladder 
Haematuria, visible Dysuria 
Haematuria, non-visible 
Raised white cell count Urinary tract infection 
Abdominal mass 
Breast 
Breast lump Breast pain 
Nipple discharge Lump in axilla 
Nipple retraction Other changes of concern, 
such as distorted breast 
contour 
Skin changes 
Colorectal 
Rectal bleeding Abdominal pain 
Iron-deficiency anaemia Faecal occult blood 
Change in bowel habit Weight loss 
Rectal mass  
Abdominal mass 
Lung 
X-ray findings suggestive of lung 
cancer 
Fatigue 
Haemoptysis Appetite loss 
Cough Chest infection 
Dyspnoea 
Thrombocytosis 
Chest pain 
Weight loss 
Finger clubbing 
Lymphadenopathy 
(supraclavicular, cervical) 
Hoarseness 
Features suggestive of lung 
metastases 
Signs of superior vena cava 
obstruction 
Stridor 
Shoulder pain 
Chest signs consistent with lung 
cancer 
Oesophagus 
and stomach 
Dysphagia Reflux 
Weight loss Haematemesis 
Upper abdominal pain 
Thrombocytosis 
Low haemoglobin/chronic 
gastrointestinal bleeding 
Dyspepsia 
Back pain 
Upper abdominal mass 
Suspicious barium meal results 
Nausea and/or vomiting 
Pancreas Jaundice 
Weight loss 
Diarrhoea 
Back pain 
Abdominal pain 
Nausea and/or vomiting 
Constipation 
New-onset diabetes 
Ovary 
Abdominal distension/bloating 
Early satiety/loss of 
appetite 
Abdominal pain Pelvic pain 
Urinary urgency/frequency Weight loss 
Abdominal/pelvic mass Fatigue 
Constipation Change in bowel habit 
Back pain 
Raised Ca125 
Ascites 
Uterus 
Postmenopausal bleeding High blood glucose 
Abdominal or pelvic mass Low haemoglobin 
Gynaecological symptoms, such as 
altered menstrual cycle, 
intermenstrual bleeding, and post- 
coital bleeding 
Reported haematuria 
Thrombocytosis 
Vaginal discharge 
Prostate 
Abnormal digital rectal 
examination 
Erectile dysfunction 
Nocturia 
Haematuria, visible 
Urinary frequency 
Urinary hesitancy 
Urinary urgency 
Urinary retention  
Table 1 (continued ) 
Cancer site Features listed in NICE 2005 (“Old 
NICE”) 
Features added in NICE 
2015 (“New NICE”) 
Raised PSA above age-specific 
value 
Myeloma 
Spinal cord compression suspected 
of being caused by myeloma 
Bone pain 
Renal failure suspected of being 
caused by myeloma 
Back pain 
Unexplained fracture 
Hypercalcaemia 
Leukopenia 
Plasma viscosity 
consistent with myeloma 
Erythrocyte 
sedimentation rate 
consistent with myeloma 
Protein electrophoresis 
suggesting myeloma 
Bence-Jones protein urine 
test suggesting myeloma  
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into “Old-NICE” and “New-NICE” categories (see Section 2.3.3). 
Exclusion criteria:  
 Scotland, where separate guidance applies [17].  
 Multiple primary cancers.  
 Cancer typical of the opposite sex; e.g. male breast cancer.  
 Screen-detected cancer, identified from NCRAS or by CPRD 
screening codes in the year before diagnosis. 
 No primary care attendance or no recorded feature of the partici-
pant’s cancer in the year before diagnosis. 
2.3. Variables and outcome measures 
2.3.1. Features of possible cancer 
CPRD codes for features of possible cancer were collated [18], based 
on the symptoms, signs or blood test results in the original or revised 
guidance (Table 1) [2,7,8]. Occurrences of these codes, restricted to the 
relevant cancer site, identified participants presenting with these fea-
tures in the year before diagnosis. Separate generic “suspected-cancer” 
codes were identified to explore for changing recording practices. 
2.3.2. Milestone dates and diagnostic interval 
The cancer diagnosis date was the earliest CPRD or NCRAS diag-
nostic code. The first recorded feature of possible cancer (index feature) 
was identified, along with the index date. Our outcome variable was 
“diagnostic interval”: days from index date to diagnosis [19]. 
2.3.3. NICE grouping 
Participants were grouped by their index feature(s) (Fig. 1, Table 1): 
 Old-NICE: participants with 1 index feature from the 2005 guid-
ance [7].  
 New-NICE: limited to participants who only had index feature(s) 
introduced during guidance revision [2,8]. 
Participants whose only index feature was a generic “suspected- 
cancer” code were omitted from analyses. 
2.3.4. Other variables 
Age and sex were identified from the CPRD year of birth, assigning a 
birthday of 1st July. 
2.4. Analyses 
Simple descriptive statistics summarised age (mean and standard 
deviation), sex (male, n, %), NICE grouping (New-NICE group, n, %), 
and the index feature(s) (n, % of all index features). We summarised 
diagnostic interval using mean (standard deviation) and the 25th, 50th, 
75th, and 90th centiles. Diagnostic interval has a skewed distribution 
and was log-transformed for analyses [13]. 
Semiparametric varying-coefficient methods estimated coefficients 
representing the percentage difference in mean log-transformed diag-
nostic interval between New-NICE and Old-NICE groups (see accom-
panying methodological paper [20]). A coefficient of 0 represents no 
difference between the NICE groups. Positive coefficients indicate that 
diagnostic intervals are longer for the New-NICE than the Old-NICE 
group; negative coefficients, that they are shorter. The coefficients are 
estimated on a daily basis, so cannot be reported using a single summary 
statistic, and are plotted (with 95 % confidence intervals, using boot-
strapping, n  1000 replications [21]) to allow visualisation over 
2006—17. The models adjusted for age and sex. Analyses examined each 
cancer site separately, sample size permitting (package “np” in R) [22]. 
Fig. 1. Schematic to show participant grouping. "Old-NICE": participants with a 
first feature of possible cancer listed in NICE 2005 (including those that have a 
first feature listed in both NICE 2005 and NICE 2015); “New-NICE”: partici-
pants whose first possible feature(s) of cancer is listed solely in NICE 2015 (or in 
NICE 2011 for ovarian cancer). 
Table 2 
Numbers of potential inclusions (individual diagnoses), with Cancer Registry linkage, and exclusions, to give final sample sizes by cancer site. The final sample is 
described in terms of size (N), age (mean, SD), number (%) who are male, and number (%) with an index cancer feature introduced during guidance revision.  
Cancer site Potential inclusions No. (%) with NCRS linkage Exclusions 
Final sample 
N Age, mean (SD) No. (%) male No. (%) in New-NICE group 
Bladder 9030 2583 (28⋅6) 3787 5243 73⋅0 (11⋅5) 3870 (73⋅8) 799 (15⋅2) 
Breast 37,369 17,452 (46⋅7) 21,827 15,542 62⋅9 (16⋅7) 0 (0) 858 (5⋅5) 
Colorectal 25,011 11,786 (47⋅1) 13,169 11,842 70⋅2 (12⋅6) 6477 (54⋅7) 5017 (42⋅4) 
Lung 20,033 9080 (45⋅3) 6926 13,107 71⋅9 (10⋅6) 7175 (54⋅7) 3384 (25⋅8) 
Myeloma 2758 1257 (45⋅6) 1224 1534 71⋅0 (11⋅5) 818 (53⋅3) 1529 (99⋅7) 
Oesophagus 6041 2710 (44⋅9) 1769 4272 71⋅3 (11⋅8) 2900 (67⋅9) 451 (10⋅6) 
Ovary 3887 1672 (43⋅0) 1406 2481 65⋅5 (13⋅8) 0 (0) 614 (24⋅7) 
Pancreas 4844 2292 (47⋅3) 1677 3167 71⋅7 (11⋅5) 1580 (49⋅9) 2672 (84⋅4) 
Prostate 30,083 14,488 (48⋅2) 8630 21,453 71⋅6 (9⋅3) 21,453 (100) 1662 (7⋅7) 
Stomach 3839 1930 (50⋅3) 1051 2788 73⋅4 (12⋅2) 1823 (65⋅4) 294 (10⋅5) 
Uterus 4382 2124 (48⋅5) 1876 2506 67⋅1 (11⋅3) 0 (0) 713 (28⋅5) 
Total 147,277a 67,374 (45⋅7) 63,342b 83,935 69⋅6 (12⋅8) 46,096 (54⋅9) 17,993 (21⋅4)  
a 147,277 cancers in 147,106 participants (of whom 317 had multiple index cancers, including cancer types not in this study). 
b 63,342 exclusions in 63,171 patients. 
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2.5. Study size 
For the descriptive statistics, we included all CPRD participants 
meeting our inclusion criteria. Semiparametric varying-coefficient an-
alyses were limited to cancer sites with participant numbers providing 
90 % power at the 5 % level to detect a 14-day difference in diagnostic 
interval between New-NICE and Old-NICE groups. Assuming mean 
diagnostic intervals of 114 and 100 days, respectively, for the Old-NICE 
and New-NICE groups, a common standard deviation of 100 days and 10 
% of participants classified as New-NICE requires 5980 total partici-
pants. An effect size of 14 days matches the two-week-wait target for 
urgent investigation. We assessed uncertainty in the estimates by con-
fidence interval width. 
2.6. Missing data and bias 
To explore for potential bias associated with changing coding prac-
tice, we identified, for annual cohorts: (a) the percentages of partici-
pants excluded for having no coded features or only suspected-cancer 
codes; (b) the proportions of Old-NICE and New-NICE participants; (c) 
demographic characteristics of participants excluded because they 
lacked coded features. 
3. Results 
3.1. Participants 
The CPRD provided 147,106 participants, of whom 63,171 (42⋅9%) 
were excluded, leaving 83,935 (57⋅1%) entering the analyses, from 603 
practices, of which 384 (63⋅7%) had NCRAS linkage (Table 2). The main 
reasons for exclusion were lack of recorded features (n  37,715), 
Scottish residence (n  17,360) and detection following screening (n 
7757) (Fig. 2). 
The sex distributions indicate male dominance in bladder (3870/ 
5243, 73⋅8 %), oesophageal (2900/4272, 67⋅9%) and stomach (1823/ 
2788, 65⋅4 %) cancers (Table 2). The overall mean (SD) age at diagnosis 
(n  83,935) was 69⋅6 years (12⋅8), ranging from 62⋅9 years (16⋅7) for 
breast to 73⋅4 years (12⋅2) for stomach (Table 2). 
3.2. NICE grouping 
The percentage of participants whose index feature was introduced 
during guidance revision (New-NICE group) varied by cancer, ranging 
from 1529/1534 (99⋅7 %) for myeloma to 858/15,542 (5⋅5%) for 
breast. More even distributions were observed for colorectal (5017/ 
11,842, 42⋅4%), lung (3384/13,107, 25⋅8 %), ovarian (614/2481, 
24⋅8%), and uterine (713/2506, 28⋅5%) cancers (Table 2). 
3.3. Index features of cancer 
Breast, bladder, and prostate cancers were dominated by one index 
feature: lump (14,200/15,662, 91⋅0%), raised prostate-specific antigen 
(14,473/22,270, 65⋅0%), and visible haematuria (3435/5346, 64⋅3%), 
respectively (Table 3). The remaining sites showed more heterogeneity. 
Colorectal cancer was characterised by abdominal pain (4291/12,084, 
35⋅5%) and rectal bleeding (3913/12,084, 32⋅4%). For lung, cough 
(4005/13,913, 28⋅8%), dyspnoea (2876/13,913, 20⋅7%), and chest 
infection (2072/13,913, 14⋅9%) were most frequent. Approximately 
half of all index features were accounted for by dysphagia (1466/4521, 
32⋅4%) and low haemoglobin (745/4521, 16⋅5%) in oesophageal 
cancer, and by low haemoglobin (943/3077, 30⋅6%), upper abdominal 
pain (479/3077, 15⋅6%), and dyspepsia (361/3077, 11⋅7%) in stomach 
cancer. Abdominal pain (925/2669, 34⋅7%) was most common in 
ovarian cancer, whereas ascites was uncommon (67/2669, 2⋅5%). 
Pancreatic cancer was characterised by abdominal pain (1068/3259, 
32⋅8%), diabetes (717/3259, 22⋅0%), and less commonly by jaundice 
Fig. 2. Application of exclusion criteria.  
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(495/2669, 15⋅2%). Postmenopausal bleeding accounted for nearly half 
of all index features of uterine cancer (1305/2619, 49⋅8%), with lower 
frequencies for high blood glucose (300/2619, 11⋅5%) and low hae-
moglobin (275/2619, 10⋅5%). 
3.4. Diagnostic interval 
Overall, the median diagnostic interval was 58 days (interquartile 
range (IQR) 23–158, N  83,935). By cancer site, the shortest diagnostic 
interval was in breast (median, IQR: 20, 10–30 days, N  15,542) and 
the longest in lung (median, IQR: 129, 46–263 days, N  13,107) 
(Table 4). 
Median (interquartile range) diagnostic intervals by year and by 
NICE grouping are plotted in Fig. 3. For all cancers combined, median 
Old-NICE diagnostic interval was 51 (interquartile range 20–132) days 
in 2006, compared with 64 (30–148) days in 2017. Median New-NICE 
diagnostic interval was longer, at 99 (40–212) days in 2006 vs 103 
Table 3 
Coded index features of cancer (n, % of total index features presenteda). Features 
are listed in order of frequency within cancer site.  
Site Feature n (% of all index 
features) 
Bladder Haematuria, visible 3435 (64⋅5)  
Urinary tract infection 847 (15⋅9)  
Dysuria 426 (8⋅0)  
Raised white cell count 427 (8⋅0)  
Haematuria, non-visible 180 (3⋅4)  
Abdominal mass 13 (0⋅2)  
Total 5328 (100) 
Breast Lump 14,200 (91⋅0)  
Breast pain 845 (5⋅4)  
Nipple discharge 253 (1⋅6)  
Nipple retraction 225 (1⋅4)  
Other changes of concern 65 (0⋅4)  
Breast skin changes 44 (0⋅3)  
Axillary lymph nodes 30 (0⋅2)  
Total 15,662 (100) 
Colorectal Abdominal pain 4291 (35⋅5)  
Rectal bleed 3913 (32⋅4)  
Change in bowel habit 1940 (16⋅1)  
Iron-deficiency anaemia 1013 (8⋅4)  
Weight loss 574 (4⋅8)  
Abdominal mass 195 (1⋅6)  
Faecal occult blood 136 (1⋅1)  
Rectal mass 22 (0⋅2)  
Total 12,084 (100) 
Lung Cough 4005 (28⋅8)  
Dyspnoea 2876 (20⋅7)  
Chest infection 2072 (14⋅9)  
Chest pain 1189 (8⋅5)  
Thrombocytosis 965 (6⋅9)  
Fatigue 558 (4⋅0)  
Shoulder pain 520 (3⋅7)  
Weight loss 485 (3⋅5)  
Haemoptysis 472 (3⋅4)  
Signs of lung metastases 270 (1⋅9)  
Hoarseness 158 (1⋅1)  
Chest signs consistent with lung cancer 125 (0⋅9)  
Appetite loss 110 (0⋅8)  
X-ray findings suggestive of lung cancer 59 (0⋅4)  
Lymphadenopathy (supraclavicular, cervical) 16 (0⋅1)  
Finger clubbing 19 (0⋅1)  
Signs of superior vena cava obstruction 12 (0⋅1)  
Stridor 2 (0⋅01)  
Total 13,913 (100) 
Myeloma Back pain 735 (44⋅5)  
Abnormal erythrocyte sedimentation rate 426 (25⋅8)  
Abnormal white cell count 189 (11⋅5)  
Hypercalcaemia 140 (8⋅5)  
Plasma viscosity consistent with myeloma 71 (4⋅3)  
Bone pain 51 (3⋅1)  
Pathological fracture 11 (0⋅7)  
Bence Jones protein 11 (0⋅7)  
Paraprotein 11 (0⋅7)  
Spinal cord compression suspected of being 
caused by myeloma 
5 (0⋅3)  
Total 1650 (100) 
Oesophagus Dysphagia 1466 (32⋅4)  
Low haemoglobin/chronic gastrointestinal 
bleeding 
745 (16⋅5)  
Dyspepsia 597 (13⋅2)  
Upper abdominal pain 402 (8⋅9)  
Reflux 357 (7⋅9)  
Back pain 345 (7⋅6)  
Thrombocytosis 208 (4⋅6)  
Weight loss 160 (3⋅5)  
Vomiting 152 (3⋅4)  
Nausea 61 (1⋅3)  
Haematemesis 26 (0⋅6)  
Upper abdominal mass 2 (0⋅04)  
Total 4521 (100) 
Ovary Abdominal pain 925 (34⋅7)  
Raised Ca125 345 (12⋅9)  
Abdominal distension/bloating 267 (10⋅0)  
Table 3 (continued ) 
Site Feature n (% of all index 
features)  
Abdominal/pelvic mass 254 (9⋅5)  
Back pain 219 (8⋅2)  
Constipation 201 (7⋅5)  
Fatigue 132 (4⋅9)  
Change in bowel habit 83 (3⋅1)  
Ascites 67 (2⋅5)  
Pelvic pain 55 (2⋅1)  
Frequency 53 (2⋅0)  
Weight loss 48 (1⋅8)  
Early satiety/appetite loss 14 (0⋅5)  
Urgency 6 (0⋅2)  
Total 2669 (100) 
Pancreas Abdominal pain 1068 (32⋅8)  
Diabetes 717 (22⋅0)  
Jaundice 495 (15⋅2)  
Back pain 373 (11⋅4)  
Constipation 236 (7⋅2)  
Weight loss 164 (5⋅0)  
Nausea 112 (3⋅4)  
Vomiting 82 (2⋅5)  
Diarrhoea 12 (0⋅4)  
Total 3259 (100) 
Prostate Raised PSA 14,473 (65⋅0)  
Lower urinary tract symptoms 5649 (25⋅4)  
Erectile dysfunction 933 (4⋅2)  
Haematuria, visible 927 (4⋅2)  
Abnormal digital rectal exam 288 (1⋅3)  
Total 22,270 (100) 
Stomach` Low haemoglobin/chronic gastrointestinal 
bleeding 
943 (30⋅6)  
Upper abdominal pain 479 (15⋅6)  
Dyspepsia 361 (11⋅7)  
Dysphagia 260 (8⋅4)  
Thrombocytosis 241 (7⋅8)  
Back pain 201 (6⋅5)  
Reflux 198 (6⋅4)  
Weight loss 133 (4⋅3)  
Vomit 130 (4⋅2)  
Nausea 68 (2⋅2)  
Haematemesis 57 (1⋅9)  
Upper abdominal mass 6 (0⋅2)  
Total 3077 (100) 
Uterus Postmenopausal bleeding 1305 (49⋅8)  
High blood glucose 300 (11⋅5)  
Low haemoglobin 275 (10⋅5)  
General gynaecological symptoms 247 (9⋅4)  
Vaginal discharge 218 (8⋅3)  
Reported haematuria 129 (4⋅9)  
Thrombocytosis 114 (4⋅4)  
Abdominal or pelvic mass 31 (1⋅2)  
Total 2619 (100)  
a Note: Some participants presented with multiple index features; hence, the 
totals are greater than the final sample sizes. 
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(42–236) days in 2017. 
New-NICE diagnostic intervals were considerably and consistently 
longer than Old-NICE values in bladder (133 vs 58 days), breast (44 vs 
15 days), pancreatic (126 vs 23 days), prostate (123 vs 77 days), and 
uterine (174 vs 50 days) cancers (Table 4, Fig. 3). Median diagnostic 
intervals were longer for New-NICE than for Old-NICE participants for 
colorectal (70 vs 51 days), oesophageal (77 vs 55 days), and lung 
(139⋅5 vs 124 days) cancers; however, this difference tended to decrease 
or disappear over time (Fig. 3). In ovarian cancer, diagnostic intervals 
were shorter in the New-NICE than in the Old-NICE group overall (56 vs 
72 days), notably in 2010—16 (Fig. 3). 
For bladder, colorectal, oesophageal, pancreatic and uterine 
cancers, median Old-NICE diagnostic intervals remained constant over 
2006–2017. They were longer in 2017 compared with 2006 for breast 
(25 vs 16 days), lung (135 vs 103 days), ovarian (100 vs 65⋅5 days), 
prostate (93 vs 80 days) and stomach (102 vs 72⋅5 days) cancers 
(Fig. 3). 
3.5. Semiparametric varying-coefficient analyses 
Semiparametric varying-coefficient analyses were powered for 
bladder, breast, colorectal, lung, prostate and uterine cancers. The 
percentage differences (with 95 % confidence intervals) in mean log- 
transformed diagnostic interval between New-NICE and Old-NICE 
groups over time are plotted in Fig. 4. 
After guidance revision on 23rd June 2015, New-NICE diagnostic 
intervals tended to shorten relative to those of the Old-NICE group in 
prostate (Fig. 4e) and uterine (Fig. 4f) cancers (note the downward 
trajectory towards the horizontal dashed line). 
For colorectal cancer, the difference in diagnostic interval between 
the New-NICE and Old-NICE groups reduced over time. After guidance 
revision, New-NICE diagnostic intervals were shorter than Old-NICE 
intervals, as indicated by the trend dropping below the horizontal 
dashed line (Fig. 4c). 
For lung cancer, New-NICE were longer than Old-NICE diagnostic 
intervals in the years 2006–10. In 2010–15, there was no difference 
between the groups. In 2016 (post guidance revision), New-NICE diag-
nostic intervals shortened relative to Old-NICE diagnostic intervals, but 
this was not sustained into 2017—18 (Fig. 4d). 
3.6. Missing data and bias 
The proportions of eligible participants excluded for lack of coded 
features increased over time for bladder, colorectal, lung, oesopha-
geal, ovarian, pancreatic, stomach, and uterine cancers. This coin-
cided with increased use of suspected-cancer codes (Fig. S1). The 
demographic details of excluded and included participants were similar 
(Table S1 and Table 2). The proportions of Old-NICE and New-NICE 
participants were largely similar across time within cancer sites 
(Fig. S2). 
4. Discussion 
4.1. Findings 
This study examined diagnostic intervals for 11 cancers in England, 
Table 4 
Diagnostic interval (25th, 50th, 75th, and 90th centiles, mean and standard deviation) by cancer site.  
Cancer site Group N 
Diagnostic interval (days) 
Centile 
Mean SD 
25th 50th 75th 90th 
Bladder New-NICE 799 61 133 239 322 153⋅2 106⋅4  
Old-NICE 4444 32 58 113 226 89⋅1 84⋅2  
Total 5243 34 64 135 253 98⋅9 90⋅9 
Breast New-NICE 858 17 44 138 272 92⋅4 101⋅4  
Old-NICE 14,684 10 15 28 53 28⋅5 43⋅7  
Total 15,542 10 16 30 62 32⋅0 50⋅8 
Colorectal New-NICE 5017 29 70 159 270 105⋅4 97⋅4  
Old-NICE 6825 25 51 105 208 80⋅7 80⋅2  
Total 11,842 27 57 126 237 91⋅2 88⋅7 
Lung New-NICE 3384 51 139⋅5 270 336 160⋅6 116⋅9  
Old-NICE 9723 44 124 260 331 152⋅4 116⋅9  
Total 13,107 46 129 263 332 154⋅5 117⋅0 
Myeloma New-NICE 1529 37 97 216 307 131⋅5 109⋅1  
Old-NICE 5 0⋅5 4 10 338 70⋅6 149⋅5  
Total 1534 37 97 216 307 131⋅3 109⋅2 
Oesophagus New-NICE 451 38 77 161 280 112⋅1 96⋅7  
Old-NICE 3821 21 55 167 293 104⋅2 106⋅8  
Total 4272 23 57 166 292 105⋅1 105⋅8 
Ovary New-NICE 614 26 56 133 281 95⋅9 99⋅0  
Old-NICE 1867 34 72 170 283 110⋅9 100⋅5  
Total 2481 31 67 160 283 107⋅2 100⋅4 
Pancreas New-NICE 2672 49 126 258⋅5 329 154⋅0 114⋅6  
Old-NICE 495 11 23 48 91 40⋅5 53⋅5  
Total 3167 35 97 232 321 136⋅3 115⋅0 
Prostate New-NICE 1662 56 123 240 321 151⋅0 107⋅9  
Old-NICE 19,791 37 77 174 287 115⋅1 99⋅7  
Total 21,453 38 80 181 291 117⋅9 100⋅8 
Stomach New-NICE 294 41 94⋅5 219 315 133⋅4 112⋅0  
Old-NICE 2494 32 88 216 314 127⋅9 111⋅7  
Total 2788 33 88⋅5 216 314 128⋅5 111⋅7 
Uterus New-NICE 713 76 174 284 337 179⋅1 112⋅5  
Old-NICE 1793 25 50 108 206 80⋅8 80⋅9  
Total 2506 30 67⋅5 167 285 108⋅7 101⋅2 
Total New-NICE 17,993 39 98 222 315 134⋅2 110⋅5  
Old-NICE 65,942 21 51 135 271 94⋅2 99⋅4  
Total 83,935 23 58 158 285 102⋅8 103⋅2  
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Wales and Northern Ireland over 2006–2017, a period including major 
revision of national suspected-cancer referral guidance. As hypoth-
esised, times to diagnosis were generally longer for “New-NICE” par-
ticipants (with index feature(s) of cancer introduced during guidance 
revision) than for “Old-NICE” participants (with feature(s) in the orig-
inal guidance). Importantly, for colorectal cancer, New-NICE diag-
nostic intervals were shorter than Old-NICE diagnostic intervals after 
guidance revision. The gap between New- and Old-NICE groups 
decreased for prostate and uterine cancers over time, consistent with 
decreasing New-NICE diagnostic intervals aided by increasing Old-NICE 
diagnostic intervals for prostate cancer. The revised national guidance 
and GP responses to its preceding evidence base may have contributed to 
these changes, along with other early-diagnosis initiatives. In conclu-
sion, scope remains to reduce time to diagnosis for symptomatic cancers 
in England, Wales and Northern Ireland. 
4.2. Strengths and limitations 
A considerable strength is the study’s primary-care setting, where 
suspected-cancer guidance is implemented. The CPRD is the largest 
primary-care database worldwide and is recognised for its high-quality 
data [23]. We used established methods for case identification [18], 
with validation of cancer diagnosis by NCRAS where linkage was 
available. NCRAS data completeness improved in 2013 [24]. Pre-2013 
studies report a concordance rate of 83⋅3% between CPRD and cancer 
registry information [25]. The CPRD diagnosis date was a median of 11 
days (interquartile range –6 to 30 days) later than the registry date 
pre-2013 for colorectal, lung, gastrointestinal, and urological cancers 
[26]. Thus pre-2013 diagnostic intervals may be overestimated 
compared with post-2013 values. Reassuringly, no step-change in New- 
or Old-NICE diagnostic intervals were observed around 2013, suggesting 
that any associated bias is small. 
We studied diagnostic interval rather than the primary care (time 
from index date to referral) or secondary care (time from referral to 
treatment) interval to avoid restricting analyses to participants referred 
to secondary care [19]. A limitation was the inability to analyse diag-
nostic intervals separately for participants referred via the 
two-week-wait pathway [27] because robust data sources for identifying 
them were unavailable to us. 
We found conflicting evidence of changes in GP recording practice 
over time. The proportion excluded for lack of coded features increased 
over time for some cancers, often coinciding with increased use of 
“suspected-cancer” codes. The proportions of Old- and New-NICE 
groups over time were constant and the similar demographic details 
for included and excluded participants suggests no marked selection 
bias. We excluded approximately 26 % of participants for lack of coded 
features, a proportion consistent with evidence that coded CPRD data 
identifies 80 % of visible haematuria or jaundice events, and 60–70 % of 
abdominal pain in patients with pancreatic or bladder cancers [28]. Of 
participants without recorded features, some will have presented at 
Emergency Departments without prior primary-care consultations [5, 
29,30], some will had the information recorded in “free text” [28], and 
others may have presented with features outside NICE guidance. Such 
features were deliberately omitted from our study, as irrelevant to our 
focus on guidance revision. 
Our analytical method allowed us to explore trends in the difference 
in diagnostic interval between groups aligned by their index feature(s) 
to the revised (New-NICE) or original (Old-NICE) guidance [20]. The 
method was derived to explore the time-varying and gradual impact of 
emerging clinical evidence that is legitimised into clinical practice by 
official guidance revision and implementation [20]. 
4.3. Comparison with existing literature 
Our findings build on previous analysis of the original 2005 NICE 
guideline’s impact on diagnostic interval [13]. Mean diagnostic interval 
Fig. 3. Median (interquartile range) diagnostic interval (days) by year of diagnosis (2006 to 2017), and by NICE grouping: New-NICE (dashed) and Old-NICE (solid).  
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for 15 UK cancers reduced between 2001–2 and 2007–8 by 5⋅4 days (95 
% CI: 2⋅4–8⋅5 days) from an initial value of 125⋅8 days. Similar to our 
study, median diagnostic intervals were shortest for cancers commonly 
presenting with lumps/masses (e.g. 26 days for breast) and longest for 
cancers often presenting with symptoms shared with other diseases (e.g. 
112 days in lung cancer) [13]. Our estimates of diagnostic interval for 
colorectal cancer are similar to those obtained by the International 
Cancer Benchmarking Partnership using different data sources [31]. Our 
findings are consistent with the taxonomy of cancer symptom “signa-
tures” and diagnostic difficulty [9]. Breast cancer had a narrow signa-
ture of a single alarm feature (breast lump) highly predictive of 
undiagnosed cancer plus the shortest diagnostic interval. In contrast, 
lung cancer had a very broad signature and the longest diagnostic 
interval. 
Jensen et al. [27] investigated the impact of implementing a stand-
ardised cancer patient pathway in Denmark in 2007–2009. 
Post-implementation diagnostic intervals were 15 (12–17) days shorter 
than peri-implementation values for the 37 % of patients actually 
referred via a cancer pathway, but were 4 (1–7) days longer for the 63 % 
of patients diagnosed via other routes. The authors concluded that the 
cancer pathways expedited diagnosis for a minority of patients. 
Fig. 4. Percentage change in diagnostic interval in New-NICE vs Old-NICE groups, by year of diagnosis (2006 to 2017) for cancers of the bladder, breast, colorectal, 
lung, prostate, and uterus. 
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4.4. Clinical interpretation and policy implications of the findings 
The relationship between diagnostic interval and mortality (and 
stage) is U-shaped, reflecting confounding by indication [32–34]. Pa-
tients with advanced tumours generally receive an expedited diagnosis 
(possibly as an emergency) and have poor outcomes because of their 
high inherent mortality: the so-called “sick-quick”. Conversely, patients 
presenting with vague symptoms usually have longer diagnostic in-
tervals, and higher mortality – thought to reflect the impact of diag-
nostic delay, particularly between referral and diagnosis [32–35]. The 
revised guidance aimed to benefit patients by legitimising doctors to 
investigate at a lower risk of undiagnosed cancer. This change can 
reduce both diagnostic delay and emergency presentation. In this study, 
for colorectal cancer, New-NICE diagnostic intervals reduced relative to 
Old-NICE interval after guidance revision. This is consistent with gen-
eral practitioners acting on the vague (“New-NICE”) features introduced 
during guidance revision. Indeed, the proportion diagnosed via the ur-
gent cancer referral pathway increased from 30 % (95 %CI 29 %–30 %) 
in 2013 to 33 % (33 %–34 %) in 2016, spanning the period of guidance 
revision [36]. 
Our findings of increasing Old-NICE diagnostic intervals over time 
may reflect growing strain on NHS diagnostic-endoscopy and imaging 
services [37], as demand for all indications (not just cancer) rises [38], 
particularly if CT-based targeted screening for lung cancer is introduced 
[39]. In 2018, inadequate diagnostic capacity was considered a 
rate-limiting step in the diagnostic pathway [40], and a negative impact 
of Covid-19 on diagnostic services is already becoming apparent [41]. 
5. Conclusions 
We conclude that scope remains to reduce time to cancer diagnosis. 
The revised colorectal cancer diagnostic guidance may be exerting a 
downward pressure on time to diagnosis of this cancer, through impacts 
on the vague features of cancer introduced during guidance revision. 
Future studies using causal analysis should examine the impact of 
guidance revision on staging at diagnosis and survival for all cancers, 
and the possible downstream effects on investigative services. Policy- 
makers are urged to enhance cancer diagnostic services so that they 
do not pose a rate-limiting step in the diagnostic pathway, and to protect 
them from the pressures of Covid-19. 
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